Souhaitez-vous accéder aux communiqués récents ?

WALTHAM, Mass., Dec. 19, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that William Heiden, president and chief executive officer, will present at the...

Next Generation Anticoagulant Reversal Agent, Ciraparantag, Will Add Innovative Clinical Stage Asset to AMAG’s Hematology Portfolio Conference call scheduled for 8:00 a.m. ET today WALTHAM, Mass.,...

WALTHAM, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that research supported by the Company, “Sustained Improvements in Fatigue and Quality of...

WALTHAM, Mass., Nov. 29, 2018 (GLOBE NEWSWIRE) -- As part of the company’s annual grant program to support research to reduce preterm birth and preeclampsia and associated complications, AMAG...

WALTHAM, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that company management will participate in the following investor conferences: Jefferies...

Achieved strong third quarter financial performance and increased full year 2018 guidance Acquired AMAG-423 for severe preeclampsia, reaffirming the company's focus on...

WALTHAM, Mass., Oct. 25, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that its third quarter 2018 financial results will be released on Thursday, November 1,...

Study Suggests that While All Postmenopausal Women Benefit from Treatment with Prasterone (INTRAROSA®), Women Experience Greatest Relief of Moderate to Severe Dyspareunia when started on INTRAROSA®...

Currently no FDA-approved treatment options for severe preeclampsia, a leading cause of maternal and neonatal mortality Acquisition expands AMAG’s maternal health portfolio and commitment to...

WALTHAM, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that together with Emmy®-nominated actress Cheryl Hines and leading family medicine and...